Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study

Breva, Lina Perez; Díez-Domingo, Javier; Beneito, Miguel Angel Martínez; Puig-Barberà, Joan

doi:10.1016/j.vaccine.2015.02.048

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research demonstrates that increasing responsibility and control over one’s own health records, including immunization history, fosters greater engagement within the health care system and increases knowledge about personal health [ 18 ]. As registries in many jurisdictions underestimate coverage [ 19 , 20 ], any mechanism that empowers the individual to record and report immunization encounters has the potential to improve immunization programs.…”

Section: Discussionmentioning

confidence: 99%

Feasibility and Limitations of Vaccine Two-Dimensional Barcoding Using Mobile Devices

Bell¹,

Guerinet²,

Atkinson³

et al. 2016

J Med Internet Res

View full text Add to dashboard Cite

BackgroundTwo-dimensional (2D) barcoding has the potential to enhance documentation of vaccine encounters at the point of care. However, this is currently limited to environments equipped with dedicated barcode scanners and compatible record systems. Mobile devices may present a cost-effective alternative to leverage 2D vaccine vial barcodes and improve vaccine product-specific information residing in digital health records.ObjectiveMobile devices have the potential to capture product-specific information from 2D vaccine vial barcodes. We sought to examine the feasibility, performance, and potential limitations of scanning 2D barcodes on vaccine vials using 4 different mobile phones.MethodsA unique barcode scanning app was developed for Android and iOS operating systems. The impact of 4 variables on the scan success rate, data accuracy, and time to scan were examined: barcode size, curvature, fading, and ambient lighting conditions. Two experimenters performed 4 trials 10 times each, amounting to a total of 2160 barcode scan attempts.ResultsOf the 1832 successful scans performed in this evaluation, zero produced incorrect data. Five-millimeter barcodes were the slowest to scan, although only by 0.5 seconds on average. Barcodes with up to 50% fading had a 100% success rate, but success rate deteriorated beyond 60% fading. Curved barcodes took longer to scan compared with flat, but success rate deterioration was only observed at a vial diameter of 10 mm. Light conditions did not affect success rate or scan time between 500 lux and 20 lux. Conditions below 20 lux impeded the device’s ability to scan successfully. Variability in scan time was observed across devices in all trials performed.Conclusions2D vaccine barcoding is possible using mobile devices and is successful under the majority of conditions examined. Manufacturers utilizing 2D barcodes should take into consideration the impact of factors that limit scan success rates. Future studies should evaluate the effect of mobile barcoding on workflow and vaccine administrator acceptance.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility and Limitations of Vaccine Two-Dimensional Barcoding Using Mobile Devices

Bell¹,

Guerinet²,

Atkinson³

et al. 2016

J Med Internet Res

View full text Add to dashboard Cite

show abstract

Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination

Pérez-Breva

Abad

Martínez-Beneito

et al. 2017

Vaccine

View full text Add to dashboard Cite

Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March–August, 2020

Lim

Delorey

Bestul

et al. 2021

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Monitoring of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence can complement case reporting to inform more accurate estimates of SARS-CoV-2 infection burden, but few studies have undertaken repeated sampling over time on a broad geographic scale. Methods We performed serologic testing on a convenience sample of residual sera obtained from persons of all ages, at ten sites in the United States from March 23 through August 14, 2020, from routine clinical testing at commercial laboratories. We age-sex-standardized our seroprevalence rates using census population projections and adjusted for laboratory assay performance. Confidence intervals were generated with a two-stage bootstrap. We used Bayesian modeling to test whether seroprevalence changes over time were statistically significant. Results Seroprevalence remained below 10% at all sites except New York and Florida, where it reached 23.2% and 13.3%, respectively. Statistically significant increases in seroprevalence followed peaks in reported cases in New York, South Florida, Utah, Missouri and Louisiana. In the absence of such peaks, some significant decreases were observed over time in New York, Missouri, Utah, and Western Washington. The estimated cumulative number of infections with detectable antibody response continued to exceed reported cases in all sites. Conclusions Estimated seroprevalence was low in most sites, indicating that most people in the U.S. have not been infected with SARS-CoV-2 as of July 2020. The majority of infections are likely not reported. Decreases in seroprevalence may be related to changes in healthcare-seeking behavior, or evidence of waning of detectable anti-SARS CoV-2 antibody levels at the population level. Thus, seroprevalence estimates may underestimate the cumulative incidence of infection.

show abstract

Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study

Cited by 3 publications

References 14 publications

Feasibility and Limitations of Vaccine Two-Dimensional Barcoding Using Mobile Devices

Feasibility and Limitations of Vaccine Two-Dimensional Barcoding Using Mobile Devices

Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination

Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March–August, 2020

Contact Info

Product

Resources

About